With nearly 30 million adults in the U.S. with diabetes, cardiologists are treating more and more patients with both established cardiovascular disease and diabetes. Recent trial evidence demonstrating cardio-protective effects of new antidiabetic drugs has introduced a lot of new questions for clinicians. Cardiologists now need to weigh evidence of cardiovascular outcomes from new antidiabetic drugs for cardiovascular patients with diabetes. The intersection between two very complicated diseases and their complementary treatment goals makes coordination of care even more important to manage cardiovascular risk for future events. SIM-CVRiD is a multistakeholder, multisponsor effort to explore CV risk management using new diabetic agents in complex comorbid patients suffering from both cardiovascular disease and diabetes through appropriate treatment and referral. The purpose of this effort is to facilitate a greater understanding of real-life challenges faced by patients, caregivers, clinicians, payers and health systems in incorporating newer agents for improved outcomes in diabetic patients who have established cardiovascular disease or who are at high risk.

SIM-CVRiD represents the next frontier, building off the conclusions, insights and tools from ACC's recent multidisciplinary stakeholder roundtables, decision pathways, aids and mobile apps. Components of SIM-CVRiD include:

  • Managing CV Disease Risk in Diabetes Roundtable: The roundtable is designed to address the recent trial evidence for new antidiabetic drugs, their demonstrated improved cardiovascular outcomes and what that means for the cardiology community. This roundtable will serve as a forum for clinical experts and other representatives to engage in a deep-dive into these pressing clinical issues and other questions that have emerged alongside the exciting new clinical trial data. Participants will address the key questions facing clinicians and work towards identifying solutions to overcoming the gaps in knowledge and barriers to care.
  • Diabetes and Cardiometabolic Disease Topic Collection: A page dedicated to diabetes and cardiometabolic disease that features relevant news articles, case challenges, and relevant resources. The objective of this page is to provide a centralized location for new scientific information on managing cardiovascular disease risk in diabetic patients.

SIM-CVRiD is supported by Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly and Company. The 2017 Managing CV Disease Risk in Diabetes Roundtable was supported by AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly and Company; Janssen Pharmaceuticals, Inc.; Novo Nordisk Inc.